FY2025 Earnings Estimate for LGND Issued By Zacks Small Cap

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) – Equities research analysts at Zacks Small Cap lifted their FY2025 earnings per share estimates for Ligand Pharmaceuticals in a research note issued to investors on Monday, December 16th. Zacks Small Cap analyst J. Vandermosten now anticipates that the biotechnology company will earn $4.63 per share for the year, up from their prior forecast of $3.85. The consensus estimate for Ligand Pharmaceuticals’ current full-year earnings is $1.73 per share.

LGND has been the topic of several other research reports. Royal Bank of Canada lifted their target price on Ligand Pharmaceuticals from $141.00 to $143.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. HC Wainwright restated a “buy” rating on shares of Ligand Pharmaceuticals in a report on Wednesday, December 11th. Oppenheimer upped their price objective on shares of Ligand Pharmaceuticals from $135.00 to $147.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Benchmark increased their target price on shares of Ligand Pharmaceuticals from $110.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Finally, Barclays boosted their price target on shares of Ligand Pharmaceuticals from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Monday. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Ligand Pharmaceuticals has an average rating of “Buy” and a consensus price target of $147.00.

Ligand Pharmaceuticals Trading Down 0.4 %

Shares of LGND stock opened at $113.94 on Wednesday. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of 45.39 and a beta of 1.01. Ligand Pharmaceuticals has a 1-year low of $67.53 and a 1-year high of $129.90. The stock’s fifty day simple moving average is $114.97 and its 200-day simple moving average is $102.92.

Institutional Investors Weigh In On Ligand Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in LGND. Woodstock Corp raised its position in shares of Ligand Pharmaceuticals by 0.3% in the third quarter. Woodstock Corp now owns 29,211 shares of the biotechnology company’s stock valued at $2,924,000 after purchasing an additional 100 shares during the period. Creative Planning grew its stake in Ligand Pharmaceuticals by 4.0% in the 3rd quarter. Creative Planning now owns 2,896 shares of the biotechnology company’s stock valued at $290,000 after buying an additional 111 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Ligand Pharmaceuticals by 23.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 661 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 125 shares during the period. Headlands Technologies LLC lifted its position in Ligand Pharmaceuticals by 21.7% during the 2nd quarter. Headlands Technologies LLC now owns 758 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 135 shares during the last quarter. Finally, Arizona State Retirement System boosted its holdings in Ligand Pharmaceuticals by 3.4% during the second quarter. Arizona State Retirement System now owns 4,708 shares of the biotechnology company’s stock valued at $397,000 after acquiring an additional 156 shares during the period. 91.28% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Andrew Reardon sold 2,000 shares of the company’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $99.60, for a total value of $199,200.00. Following the completion of the sale, the insider now directly owns 22,534 shares in the company, valued at approximately $2,244,386.40. This represents a 8.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director John L. Lamattina sold 2,406 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $123.65, for a total value of $297,501.90. Following the transaction, the director now owns 29,515 shares in the company, valued at approximately $3,649,529.75. This trade represents a 7.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,178 shares of company stock worth $1,485,824. Insiders own 5.90% of the company’s stock.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.